Search results
May 31, 2022 · Yiannis Monovoukas and Monte Stettin Appointed as Advisors and Observers to the Board of Directors of Athos Therapeutics. "It is a great privilege to join the Athos team in an advisory role and...
May 31, 2022 · ATH-63, the Company's lead drug compound, is moving into a Phase Ia human clinical trial in 2022. The Athos pipeline includes small molecule approaches for various autoimmune disease and cancer. View original content to download multimedia: https://www.prnewswire.
Monte Stettin is a C class executive and entrepreneur with a career spanning publishing… · Experience: Athos Therapeutics Inc · Education: New College Hofstra · Location: Beverly Hills · 500 ...
May 31, 2022 · LOS ANGELES, May 31, 2022 /PRNewswire/ -- Athos Therapeutics, Inc. (the 'Company'), a late-stage preclinical biotech company using artificial inte...
Monte Stettin’s Post Monte Stettin Advisor & Board Observer at Athos Therapeutics 10mo Report this post Report Report. Back ...
Monte Stettin’s Post Monte Stettin Advisor & Board Observer at Athos Therapeutics 2d Report this post It’s a special privilege to work with these brilliant scientists and their gifted team who ...
About monte stettin on Medium. entrepreneur, advisor, investor, technologist, sustainable real estate developer, award winning author, benefactor Singularity University, keynote speaker.
